in-PharmaTechnologist (IPT) speaks to Ettore Cucchetti (EC), CEO of ACGI, about how the biopharma industry is adapting to the threat of counterfeit medicine and how he expects the industry will adopt further measures beyond those stipulated in the EU...
A directive granting Belgium, Greece and Italy a six-year reprieve in serialisation adoption has raised concerns delayed implementation could be an opportunity for drug counterfeiters.
Pharma and CMOs must start addressing their serialization needs ahead of 2019’s EU Falsified Medicines Directive, says Tracelink which is bringing its supply chain event NEXUS to Barcelona next month.
Industry efforts set up a drug database to help Europeans identify fake pharmaceuticals progressed this week after thee software firms signed development deals with project leader, EMVO.
In a sweeping report on the industry as a whole, the European Commission says that with an annual output of €220bn, and nearly 800,000 employees, the pharma industry is vital for the EU economy, though more needs to be done to meet its full potential.
The European Commission (EC) has increased the pressure on Ireland, Italy, Poland and Slovenia to fall into line with other EU member States and introduce anti-drug counterfeiting legislation.
European dependence on drugs and APIs made outside the EU is still ‘alarming’ despite recently introduced anti-falsified meds laws according to the European Fine Chemicals Group (EFCG).
US drugmakers must stop ‘doing the minimum’ and put patient safety at the heart of their audit plans according to excipient industry expert Chris Moreton from FinnBrit Consulting.
In an effort to stave off expected drug shortages, the EC has approved a waiver that will allow US API manufacturers to export their products to Europe.
European API distributors may see costs increase if guidelines requiring quality systems and ‘management representatives’ at distribution points are adopted.
Guy Villax, board member of the EFCG, talks falsified APIs, EU efforts to tackle the issue, and the presence of gangsters in the pharma industry in an in-PharmaTechnologist video interview.
